Abstract Details

Title Sleep Impairment And Quality Of Life In Distal Symmetric Polyneuropathy Participants With Moderate To Severe Pain

Topic Sleep

Presentation(s) P1 - Poster Session 1 (8:00 AM-9:00 AM)

Poster/Presentation
Number 6-010

Objective To measure cross-sectionally sleep and quality of life perception in Distal Symmetric Polyneuropathy (DSP) participants with moderate to severe pain versus participants with none or mild pain.

Background Painful DSP is associated with reports of sleep impairment with worse pain perception affecting quality of life.

Design/Methods Participants with DSP were administered questionnaires including Pittsburgh Sleep Quality Index(PSQI), Insomnia Severity Index(ISI), Epworth Sleepiness Scale(ESS), and NeuroQoLs. DSP diagnoses were confirmed by neurologists. Painful DSP was defined based on reporting moderate to severe pain (pain severity score > 4) on the Brief Pain Inventory (BPI) short form. Non-painful DSP was defined as none or mild pain (pain severity score < 4) on the BPI.

Results 42.9% of participants were female (21/49) with a median 66±12.9 years. Median BMI was 26.2 ± 6.1kg/m². The prevalence of painful DSP was 14/49 (28.6%). Mean ISI scores were significantly greater for the painful group (16.0 ± 8.18, moderate insomnia) compared to the non-painful group (7.37 ± 5.99, subthreshold insomnia ; p=0.0002), as were PSQI scores (9.93 ± 5.27 vs 6.63 ± 4.12; p=0.0239). However ESS scores were not significantly different between the two groups (8.36 ± 5.73 vs 5.86 ± 4.71; p=0.1216). Participants with painful neuropathy also had worse NeuroQoL sleep (62.2 vs 47.4; p<0.001), fatigue (53.8 vs 43.8; p=0.004), anxiety (57.6 vs 47.0; p<0.001), and depression (53.1 vs 43.9; p<0.001).

Conclusions In this sample, insomnia, sleep quality, and QoL related to sleep, fatigue, anxiety, and depression were significantly worse in DSP patients with worse pain as measured by the BPI. Strategies to address sleep in patients with DSP may improve pain and quality of life. Further investigation of drivers of sleep impairment in DSP may provide an additional treatment strategy for management of neuropathic pain in DSP.

Authors/Disclosures
Nnenna Edeoga, Undergraduate student PRESENTER	Miss Edeoga has nothing to disclose.
Lea Saab	Miss Saab has nothing to disclose.
Alicia Yang	Miss Yang has nothing to disclose.
Sophia T. Tong	Ms. Tong has nothing to disclose.
Julia Greenberg, MD	Dr. Greenberg has a non-compensated relationship as a Editorial Board Member with Neurology Resident and Fellow Section that is relevant to AAN interests or activities.
Christina Marini	Ms. Marini has nothing to disclose.
Azizi Seixas, PhD	Dr. Seixas has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Idorsia. Dr. Seixas has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Moshikids. The institution of Dr. Seixas has received research support from Merck.
Kiril Kiprovski, MD (NYU-Langone Health)	Dr. Kiprovski has nothing to disclose.
Sujata P. Thawani, MD (NYU Neurology Associates)	Dr. Thawani has nothing to disclose.

��ɫ��

��ɫ��